Comparing tissues that were among the top 25% expression of both ANGPTL4 and APOL1 (Fig. 3A) or ITGB4 (Fig. 3B) to those that were among the bottom 25% expression of both ANGPTL4 and APOL1 or ITGB4 we saw significant differences in overall survival, with overall survival being worse for TCGA-PAAD patients with high ANGPTL4 combined with high APOL1 (p = 0.014) or ITGB4 (p = 0.01) expression. This evidence concerns the gene ANGPTL4 and pancreatic adenocarcinoma.